Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.

BACKGROUND: Identification of predictive markers of response to treatment is a major objective in breast cancer. A major problem in clinical sampling is the variability of RNA templates, requiring accurate management of tumour material and subsequent analyses for future translation in clinical practice. Our aim was to establish the feasibility and reliability of high throughput RNA analysis in a prospective trial. METHODS: This study was conducted on RNA from initial biopsies, in a prospective trial of neoadjuvant chemotherapy in 327 patients with inoperable breast cancer. Four independent centres included patients and samples. Human U133 GeneChips plus 2.0 arrays for transcriptome analysis and quantitative RT-qPCR of 45 target genes and 6 reference genes were analysed on total RNA. RESULTS: Thirty seven samples were excluded because i) they contained less than 30% malignant cells, or ii) they provided RNA Integrity Number (RIN) of poor quality. Among the 290 remaining cases, taking into account strict quality control criteria initially defined to ensure good quality of sampling, 78% and 82% samples were eligible for transcriptome and RT-qPCR analyses, respectively. For RT-qPCR, efficiency was corrected by using standard curves for each gene and each plate. It was greater than 90% for all genes. Clustering analysis highlighted relevant breast cancer phenotypes for both techniques (ER+, PR+, HER2+, triple negative). Interestingly, clustering on trancriptome data also demonstrated a "centre effect", probably due to the sampling or extraction methods used in on of the centres. Conversely, the calibration of RT-qPCR analysis led to the centre effect withdrawing, allowing multicentre analysis of gene transcripts with high accuracy. CONCLUSIONS: Our data showed that strict quality criteria for RNA integrity assessment and well calibrated and standardized RT-qPCR allows multicentre analysis of genes transcripts with high accuracy in the clinical context. More stringent criteria are needed for transcriptome analysis for clinical applications.

Mots clés

neoadjuvant setting transcriptome RT-qPCR breast cancer quality criteria

Domaines

Cancer

Fichier principal

1471-2407-11-215.pdf (220.42 Ko)

1471-2407-11-215-S1.PDF (85.32 Ko)

1471-2407-11-215-S2.PDF (96.1 Ko)

1471-2407-11-215-S3.PDF (49.77 Ko)

1471-2407-11-215-S4.PDF (49.68 Ko)

1471-2407-11-215-S5.PDF (52.12 Ko)

1471-2407-11-215-S6.PDF (47.84 Ko)

1471-2407-11-215-S7.PDF (51.52 Ko)

1471-2407-11-215-S8.PDF (48.1 Ko)

1471-2407-11-215.xml (69.38 Ko)

Origine : Fichiers éditeurs autorisés sur une archive ouverte

Format : Autre

Ed. BMC : Connectez-vous pour contacter le contributeur

https://inserm.hal.science/inserm-00663653

Soumis le : vendredi 27 janvier 2012-13:59:25

Dernière modification le : vendredi 19 avril 2024-16:18:57

Dates et versions

inserm-00663653 , version 1 (27-01-2012)

Identifiants

HAL Id : inserm-00663653 , version 1
DOI : 10.1186/1471-2407-11-215
PUBMED : 21631949

Citer

Patricia de Cremoux, Fabien Valet, David Gentien, Jacqueline Lehmann-Che, Véronique Scott, et al.. Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.. BMC Cancer, 2011, 11 (1), pp.215. ⟨10.1186/1471-2407-11-215⟩. ⟨inserm-00663653⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM UNIV-PARIS7 INSTITUT-TELECOM ENSMP ENSMP_CBIO PARISTECH FNCLCC IGR CURIE PSL FRANCE-GENOMIQUE CUBIC

386 Consultations

518 Téléchargements